Topics

Bayer in frame to win first EU nod for high-precision cancer drug

05:47 EDT 26 Jul 2019 | Reuters

Europe's drug regulator has recommended approving Bayer's Vitrakvi, putting the medicine on track to become the first in Europe to tackle tumours with a specific genetic mutation regardless of where in the body the disease started.

Original Article: Bayer in frame to win first EU nod for high-precision cancer drug

NEXT ARTICLE

More From BioPortfolio on "Bayer in frame to win first EU nod for high-precision cancer drug"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...